Table 2

Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic individuals

Population Mycoplasma genitalium prevalence
Macrolide resistance prevalence
Resistant MG
N.; % (95% CI)
Total MG
N.; % (95% CI)
Total individuals tested (N)
Women1; 10.0 (0.3 to 44.5)10; 4.5 (2.2 to 8.1)222
 Vagina1; 14.3 (0.4 to 57.9)7*; 3.2 (1.3 to 6.4)222
 Rectum0; 0.0 (0.0 to 60.2)4; 6.9 (1.9 to 16.7)58
MSW†1; 10.0 (0.3 to 44.5)10; 5.6 (2.7 to 10.0)179
MSM32; 69.6 (54.2 to 82.3)46; 9.4 (7.0 to 12.3)489
 Urethra8‡; 88.9 (51.8 to 99.7)9‡; 1.8 (0.8 to 3.5)489
 Rectum27; 67.5 (50.9 to 81.4)40; 8.5 (6.1 to 11.4)471
Total34; 51.5 (38.9 to 64.0)66; 7.4 (5.8 to 9.3)890
  • Percentages of macrolide resistance are calculated from the MG infections reported.

  • *One woman had infections in both vagina and rectum.

  • †All infections in MSW occurred in urethra.

  • ‡Three MSM had infections in both urethra and rectum.

  • MG, Mycoplasma genitalium; MSM, men who have sex with men; MSW, men who have sex with women.